Loading...
TECX logo

Tectonic Therapeutic, Inc.NasdaqGM:TECX Stock Report

Market Cap US$689.4m
Share Price
n/a
1Y64.6%
7D8.4%
1D-2.9%
Portfolio Value
​
View

Tectonic Therapeutic, Inc.

NasdaqGM:TECX Stock Report

Market Cap: US$689.4m

Tectonic Therapeutic (TECX) Stock Overview

A biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). More details

TECX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Earnings are forecast to decline by an average of 16.9% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years


TECX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW484,853 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
484,853 investors already sharing narratives
View all narratives

Tectonic Therapeutic, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Tectonic Therapeutic
Historical stock prices
Current Share PriceUS$35.48
52 Week HighUS$39.53
52 Week LowUS$14.39
Beta0.098
1 Month Change21.92%
3 Month Change14.12%
1 Year Change64.64%
3 Year Changen/a
5 Year Changen/a
Change since IPO108.58%

Recent News & Updates

Seeking Alpha • May 19

Tectonic Therapeutics: Currently In A Catalyst Vacuum

Summary Tectonic Therapeutics (TECX) targets the large, unmet PH-HFpEF market with TX45, a long-acting relaxin analog, aiming for blockbuster potential. TX45 showed promising Phase 1b results, with significant reductions in pulmonary pressures and strong safety, but faces skepticism after competitor failures. Phase 2 APEX topline data for TX45, expected year end 2026, is a high-stakes catalyst and the company has a cash runway until yearend 2028. An analysis around Tectonic Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • Nov 10

Companies Like Tectonic Therapeutic (NASDAQ:TECX) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Recent updates

Seeking Alpha • May 19

Tectonic Therapeutics: Currently In A Catalyst Vacuum

Summary Tectonic Therapeutics (TECX) targets the large, unmet PH-HFpEF market with TX45, a long-acting relaxin analog, aiming for blockbuster potential. TX45 showed promising Phase 1b results, with significant reductions in pulmonary pressures and strong safety, but faces skepticism after competitor failures. Phase 2 APEX topline data for TX45, expected year end 2026, is a high-stakes catalyst and the company has a cash runway until yearend 2028. An analysis around Tectonic Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • Nov 10

Companies Like Tectonic Therapeutic (NASDAQ:TECX) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • May 20

We Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Apr 23

Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF

Summary We initiate a Buy rating on Tectonic Therapeutic due to promising data for TX45. TX45 showed positive interim Phase 1b results, but the APEX Phase 2 trial with 180 patients will be crucial for validating its efficacy and safety. TX2100 targets hereditary hemorrhagic telangiectasia with promising preclinical data, aiming for a Phase 1 launch in late 2025 or early 2026. Financially, TECX has a strong cash position to fund operations into late 2028 but faces significant risks if clinical trials do not meet expectations. Read the full article on Seeking Alpha
Seeking Alpha • Feb 05

Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data

Summary Positive interim results released from phase 1b study, using TX45 for the treatment of patients with pulmonary hypertension heart failure with preserved ejection fraction. Data from phase 1b study using TX45 for the treatment of patients with pulmonary hypertension heart failure with reduced ejection fraction, expected in 2nd half of 2025. In the 7 major markets, the heart failure market is expected to grow to $33.7 billion in 2032. TX2100 is another candidate in the company's pipeline which is currently undergoing IND-enabling studies to target patients with Hemorrhagic Telangiectasia; Phase 1 study expected Q4 2025/Q1 2026. Read the full article on Seeking Alpha
Seeking Alpha • Jan 30

Tectonic Therapeutic: Stock Spikes On Heart Failure Data -- Why I See Further Upside

Summary Tectonic Therapeutic, Inc.'s stock surged 120% after positive Phase 1b data for TX45 in treating PH-HFpEF, a condition with no approved therapies. TX45, an Fc-relaxin fusion protein, showed promising hemodynamic improvements and safety, potentially addressing both pulmonary and cardiac aspects of PH-HFpEF. Despite concerns over small data sets and past failures of similar drugs, Tectonic's experienced management and promising data make TECX stock an intriguing “Buy” opportunity. Investors may consider waiting for further data or fundraising announcements to mitigate risks, but the potential market opportunity is significant. Read the full article on Seeking Alpha
Analysis Article • Jan 10

We Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Dec 30

Tectonic Therapeutic: Waiting For A Pullback

Summary Tectonic Therapeutic, Inc. has seen a significant stock rally which has seen its shares nearly triple since this summer. The rally has been driven by analyst optimism and the initiation of Phase 2 trials for its lead asset TX45. This compound has the potential to be a 'best of breed' product for a large untreated population. What is ahead for Tectonic Therapeutic and its shareholders in 2025?  An analysis follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Oct 20

Tectonic Therapeutic: Interesting CV Disease Drug Developer

Summary Tectonic Therapeutic's lead candidate TX45 showed positive phase 1 results for Group 2 Pulmonary Hypertension, driving the stock up over 100% in September. TX45 is an Fc-relaxin fusion molecule targeting the RXFP1 receptor, offering potential therapeutic benefits for hypertension and heart failure with preserved ejection fraction (HFpEF). Tectonic has a solid financial position with a market cap of $551mn, $185mn in cash reserves, and a cash runway extending into 2027. Despite early-stage development and competition from AstraZeneca, TECX is promising, with strong support from Wells Fargo and a long cash runway. Read the full article on Seeking Alpha
Analysis Article • Sep 22

Here's Why We're Not Too Worried About Tectonic Therapeutic's (NASDAQ:TECX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Aug 05

Tectonic Therapeutic: Analyzing Its Post-Merger Valuation And Prospects

Summary Tectonic Therapeutic, Inc. is a biotechnology company focusing on therapeutic biologics targeting GPCRs through its GEODe platform. TECX emerged after a merger with Avrobio, combining gene therapy expertise with GPCR-targeted protein development. The lead drug candidate, TX45, is in Phase 1 trials for pulmonary hypertension due to heart failure with preserved ejection fraction (HFpEF). The company's cash runway is expected to last until mid-2027, potentially necessitating future capital raises. TECX's valuation appears relatively cheap compared to peers, but its early-stage research and cash burn risks lead me to a neutral stance. Read the full article on Seeking Alpha

Shareholder Returns

TECXUS BiotechsUS Market
7D8.4%4.0%-0.7%
1Y64.6%42.5%20.3%

Return vs Industry: TECX exceeded the US Biotechs industry which returned 42.5% over the past year.

Return vs Market: TECX exceeded the US Market which returned 20.3% over the past year.

Price Volatility

Is TECX's price volatile compared to industry and market?
TECX volatility
TECX Average Weekly Movement8.7%
Biotechs Industry Average Movement10.4%
Market Average Movement7.3%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: TECX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: TECX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a60Alise Reicintectonictx.com

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin.

Tectonic Therapeutic, Inc. Fundamentals Summary

How do Tectonic Therapeutic's earnings and revenue compare to its market cap?
TECX fundamental statistics
Market capUS$689.39m
Earnings (TTM)-US$83.49m
Revenue (TTM)n/a
0.0x
P/S Ratio
-8.0x
P/E Ratio

Is TECX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TECX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$83.49m
Earnings-US$83.49m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-4.42
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did TECX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/08 23:59
End of Day Share Price 2026/07/08 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tectonic Therapeutic, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David RisingerLeerink Partners LLC
Cory JubinvilleLifeSci Capital, LLC
Uy EarMizuho Securities USA LLC